Justin Thomas, MD
Medical Oncology · Bozeman, MTNPI 1104002195
Payments from drug & device makers
Across 296 payments — averaging $3258.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$578K
- Pfizer$201K
- AstraZeneca$182K
- Johnson & Johnson$1K
- AbbVie$657
- Lilly USA, LLC$253
- plus $2K from 23 others
What the payments were for
- Consulting fees$2,26526%
- Travel & lodging$2,60030%
- Food & beverage$3,79643%
- Education$1261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 77 | $578,247 |
| Pfizer | 50 | $200,694 |
| AstraZeneca(2 entities) | 31 | $181,663 |
| Johnson & Johnson(2 entities) | 49 | $1,491 |
| AbbVie | 4 | $657 |
| Lilly USA, LLC | 13 | $253 |
| Bristol Myers Squibb | 10 | $179 |
| Blueprint Medicines Corporation | 1 | $135 |
| GSK | 7 | $134 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $132 |
| E.r. Squibb & Sons, L.L.C. | 5 | $116 |
| Stemline Therapeutics Inc. | 4 | $114 |
| Janssen Scientific Affairs, LLC | 2 | $112 |
| AVEO Pharmaceuticals, Inc. | 6 | $110 |
| Novartis | 4 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| Seagen Inc. | 3 | $65 |
| Servier Pharmaceuticals LLC | 3 | $61 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Pharming Healthcare, Inc. | 2 | $47 |
| Sanofi | 3 | $44 |
| Aadi Bioscience, Inc. | 2 | $41 |
| Caris MPI, Inc. | 1 | $36 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $20 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 32 | $440,627 |
| IbrancePalbociclib | 25 | $401,921 |
| ImbruvicaIbrutinib | 22 | $381,325 |
| Lenalidomide | 28 | $226,293 |
| VenclextaVenetoclax | 23 | $209,713 |
| TagrissoOsimertinib Mesylate | 11 | $207,925 |
| JakafiRuxolitinib Phosphate | 13 | $181,141 |
| LynparzaOlaparib | 11 | $116,686 |
| TasignaNilotinib Hcl | 11 | $115,439 |
| Abiraterone Acetate | 30 | $35,517 |
| CreonLipase/Protease/Amylase | 12 | $21,083 |
| EliquisApixaban | 19 | $18,349 |
| XareltoRivaroxaban | 15 | $14,805 |
| Anastrozole | 63 | $1,259 |
| Prochlorperazine Maleate | 55 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $200,694 | $420,27044 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $132 | $381,32522 claims |
| AstraZenecaTagrisso, Lynparza | $181,663 | $324,61122 claims |
| AbbVieVenclexta, Creon | $657 | $230,79735 claims |
| Incyte CorporationJakafi | $19 | $181,14113 claims |
| NovartisTasigna | $78 | $115,43911 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $112 | $35,51730 claims |
| Johnson & JohnsonXarelto | $1,491 | $14,80515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Montanaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Bozeman
- Kara SchenkBozeman$253K
- Kenneth MayBozeman$685
- Bryan MartinGreat Falls$1K
- Jose NessKalispell$351
- Robert JosephSidney$137
- Siobhan LynchMissoula$131
- James BurkeBillings$91
- Michael GoodmanRonan$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.